Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

Arena Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Ulcerative Colitis

Treatments: Drug: Placebo; Drug: Etrasimod

Study type: Interventional

Funder types: Industry

Identifiers

NCT02536404

APD334-005

Details and patient eligibility

About

The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.

Enrollment: 118 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants who completed the APD334-003 (NCT02447302) study

Exclusion criteria

• Participants who did not complete the APD334-003 study

Trial design

118 participants in 2 patient groups

Etrasimod 2 mg

Experimental group

Treatment:

Drug: Etrasimod

Placebo

Active Comparator group

Treatment:

Drug: Placebo